Supernus Pharmaceuticals (SUPN) Cash from Operations Growth (1y) (2012 - 2026)
Supernus Pharmaceuticals (SUPN) Cash from Operations Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 425.00% |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.36 Bn | - | 117.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 117.41% |
| Dec 31, 2025 | -55.27% |
| Sep 30, 2025 | -215.22% |
| Jun 30, 2025 | 64.31% |
| Mar 31, 2025 | -20.32% |
| Dec 31, 2024 | -1.23% |
| Sep 30, 2024 | 49.18% |
| Jun 30, 2024 | 288.75% |
| Mar 31, 2024 | -21.83% |
| Dec 31, 2023 | 63.10% |
| Sep 30, 2023 | 159.19% |
| Jun 30, 2023 | -126.54% |
| Mar 31, 2023 | 1,041.93% |
| Dec 31, 2022 | -43.47% |
| Sep 30, 2022 | 436.76% |
| Jun 30, 2022 | 53.69% |
| Mar 31, 2022 | -88.12% |
| Dec 31, 2021 | 52.70% |
| Sep 30, 2021 | -173.41% |
| Mar 31, 2021 | 306.01% |